MAPK3 and asthma: Our data clearly show that treatment with OBE both reverses the asthma phenotype, once established, and reduces its severity when administered prior to the immunization and this occurs via inhibition of several mechanisms such as IgE, IgE-dependent allergic inflammation, numerous cytokines and chemokines and the EGFR, ERK1/2 and AKT signaling pathways.